Lek opens new production unit in Slovenia

Ljubljana, Slovenia-based generics drugmaker Lek, a subsidiary of the Swiss Novartis group, has this month opened its first unit for organic synthesis at Menges, near Ljubljana, involving an investment of 2 billion tolars ($10.4 million), according to the STA news service. The unit will produce ingredients for drugs used in the treatment of hypertension and cholesterol disorders, which the company will sell in the European Union, the USA and Japan. The new unit adds to one for biopharmaceutical production opened in February at a cost of $22.5 million.